Rapamycin and rapalogs for tuberous sclerosis complex-Reference-Cited by-同舟云学术

Rapamycin and rapalogs for tuberous sclerosis complex

Published:2016-07-13 Issue:6 Volume:2017 Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Sasongko Teguh H¹,Ismail Nur Farrah Dila²,Zabidi-Hussin ZAMH³⁴

Affiliation:

1. International Medical University; Human Biology Division, School of Medicine; No. 126, Jalan Jalil Perkasa 19, Bukit Jalil Kuala Lumpur Malaysia 57000

2. Universiti Sains Malaysia; Human Genome Center, School of Medical Sciences; 16150 Kubang Kerian Kota Bharu Kelantan Malaysia

3. Universiti Sains Malaysia; Center for Neuroscience Services and Research; Kelantan Malaysia

4. Universiti Sains Malaysia; Department of Pediatrics, School of Medical Sciences; USM Health Campus Kubang Kerian Kelantan Malaysia

Publisher

Wiley

Subject

Pharmacology (medical)

Reference116 articles.

1. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial;Bissler;Lancet,2013

2. NCT00790400 Efficacy and safety of RAD001 in patients aged 18 and over with Angiomyolipoma associated with either tuberous sclerosis complex (TSC) or sporadic lymphangioleiomyomatosis (LAM) (EXIST-2) https://www.clinicaltrials.gov/ct2/show/study/NCT00790400?term=NCT00790400&rank=1

3. Franz D Lam D Cauwel H Jozwiak S Effect of everolimus on subependymal nodules (SENs) and tubers in patients with subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC): Results from the exist-1 trial [abstract] Proceedings of the 65th American Academy of Neurology Annual Meeting San Diego, CA United States Lippincott Williams and Wilkins 2013

4. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial;Franz;Lancet,2013

5. Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2-year open-label extension of the randomised EXIST-1 study;Franz;The Lancet. Oncology,2014

Cited by 53 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tuberous Sclerosis Complex and the kidneys: what nephrologists need to know;Brazilian Journal of Nephrology;2024-09

2. Clinical practice recommendations for kidney involvement in tuberous sclerosis complex: a consensus statement by the ERKNet Working Group for Autosomal Dominant Structural Kidney Disorders and the ERA Genes & Kidney Working Group;Nature Reviews Nephrology;2024-03-05

3. Terminology and Classifications of Vascular Lesions Based on Molecular Identification;Oral and Maxillofacial Surgery Clinics of North America;2024-02

4. Therapeutic Strategies for Gliomas Associated With Cancer Predisposition Syndromes;JCO Precision Oncology;2024-02

5. Efficacy and Safety of Topical Sirolimus for the Treatment of Angiofibromas in Tuberous Sclerosis: a Systematic Review and Meta-analysis;Current Pharmacology Reports;2023-12-13